Aviragen Therapeutics (AVIR) Delays Q4 Conference Call
- Wall St lackluster ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Stocks head into quarter-end on the up; yen on intervention watch
- Dollar gains on euro with Fed's Waller hawkish on rates
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Timken (TKR) Appoints Tarak Mehta as New CEO
Aviragen Therapeutics Announces Schedule Change for Fourth Quarter and Fiscal Year End 2016 Financial Results Conference Call and Webcast
September 6, 2016 5:34 PM EDTATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ: AVIR), (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016 earnings conference call and webcast while it concludes discussions involving the... More